NCT04636632View on ClinicalTrials.gov

Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

PHASE1CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

November 4, 2022

Study Completion Date

November 4, 2022

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

fosaprepitant

fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT04636632 - Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter